Experiences of the DREAM trial;A DREAM vizsgálat tapasztalatai

Orvosi Hetilap

Volumn 147, Issue 52, 2006, Pages 2523-2526

  Fövényi, József ^a,b  

^a Peterfy Sandor Utcai Korhaz   (Hungary)

^b NONE   (Hungary)

Author keywords

Diabetes prevention; Impaired fasting glucose; Impaired glucose tolerance; Ramipril; Rosiglitazone; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; INSULIN; PLACEBO; RAMIPRIL; ROSIGLITAZONE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEATH; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 34247866399     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Buchanan, T. A., Xiang, A. H., Peters, R. K. és mtsai: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes, 2002, 51, 2796-2803.
2. Chiasson, J-L., Josse R. G., Gomis, R. és mtsai: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359, 2072-2077.
3. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 2002, 346, 393-403.
4. Diabetes Prevention Program Research Group: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes, 2005, 54, 1150-1156.
5. DREAM Trial Investigators: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia, 2004, 47, 1819-1527.
6. Julius, S., Kjeldsen, S. E., Weber, M. és mtsai: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan of amlodipine: the VALUE randomised trial. Lancet, 2004, 363, 2022-2031.
7. Leiter, L. A.: Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabet. Med., 2005, 22, 963-972.
8. Roglic, G., Unwin, N., Bennett, P. H. és mtsai: The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care, 2005, 28, 2130-2135.
9. The DREAM Trial Investigators: Effect ol ramipril ont he incidence of diabetes. N. Engl. J. Med., 2006, 355, 1551-1562.
10. The DEAM trial investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controller trial. Lancet, 2006, 368, 1096-1105.
11. Tuomüehto, J., Lindstrom, Z, Eriksson, J. G és mtsai: Prevention of type 2 diabetes mellitus by changes in lilestyle among subjects with impaired glucose tolerance. N. Engl. J. Med., 2001, 344, 1343-1350.
12. Unwin, N., Shaw, J., Zimmet, P. és mtsai: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet. Med., 2002, 19, 708-723.
13. Vermes, E., Ducharme, A., Bourassa, M. G. és mtsai: Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight kom the Studies Of Left Ventricular Dysfunction (SOLVD) Circulation, 2003, 107, 1291-1296.
14. Yki-Jarvinen, H.: Fat in the liver and insulin resistance. Ann. Med., 2005, 37, 347-356.
15. Yusuf, S., Gerstein, H., Hoogwerf, B. és mtsai: Ramipril and the development of diabetes JAMA, 2001, 286, 1882-1885.
16. Yusuf, S., Ostergren, J. B., Gerstein, H. C. és mtsai: Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation, 2005, 112, 48-53.